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Even in the 21st century, we are losing the battle against eradication of tuberculosis (TB). In
2015, 9.6 million people were estimated to have fallen ill with TB, of which 1.5 million peo-
ple died. This is the real situation despite the well-structured treatment programs and
availability of effective treatment options since the 1950s. The high mortality rate has been
associated with other risk factors, such as the HIV epidemic, underlying diseases, and
decline of socioeconomic standards. Furthermore, the problem of drug resistance that
was recognized in the early days of the chemotherapeutic era raises serious concerns.
Although resistance to a single agent is the most common type, resistance to multiple
agents is less frequent but of greater concern. The World Health Organization estimated
approximately 5% of all new TB cases involved multidrug-resistant (MDR)-TB. The estima-
tion for MDR-TB is 3.3% for new cases, and 20.5% for previously treated cases. Failure to
identify and appropriately treat MDR-TB patients has led to more dangerous forms of resis-
tant TB. Based onWorld Health Organization reports, 5% of global TB cases are now consid-
ered to be extensively drug resistant (XDR), defined as MDR with additional resistance to
both fluoroquinolones and at least one second-line injectable drug. XDR-TB had been
reported by 105 countries by 2015. An estimated 9.7% of people with MDR-TB have XDR-
TB. More recently, another dangerous form of TB bacillus was identified, which was named
totally drug resistant (TDR-TB) or extremely drug resistant TB. These strains were resistant
to all first- and second-line anti-TB drugs. Collectively, it is accepted that 2% of MDR-TB
strains turn to be TDR-TB. This number, however, may not reflect the real situation, as
many laboratories in endemic TB countries do not have proper facilities and updated pro-
tocols to detect the XDR or TDR-TB strains. Nevertheless, existing data emphasize the need
for additional control measures, such as new diagnostic methods, better drugs, and more
effective vaccines to prevent the spread of these strains around the world.Conflict of interest
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